X-Cell Medical, Inc.

Enrollment complete in trial of beta-estradiol eluting stent system

Published in Lab Business Week, January 1st, 2006

X-Cell Medical, Inc. announced that the company has completed enrollment in its multinational clinical trial to study the safety and effectiveness of the Ethos I Coronary Stent System. Ethos I stents are coated with slow-release and moderate-release formulations of 17 beta-estradiol, an approved and safe drug used in hormone replacement therapy and other indications.

An overview of the potential cardioprotective and safety benefits of using estradiol to reduce restenosis in human coronary arteries and the ETHOS I study design was presented at the 2005 Transcatheter Cardiovascular Therapeutic symposium (TCT) by Alexandre Abizaid, MD, PhD, Cardiovascular Research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-01-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry